In fact, combined PD-1/PD-L1 and NKG2A/HLA-E immunotherapy has demonstrated an improved objective response in a Phase 2 clinical trial of patients with nonresectable, stage III non-small-cell lung cancer [57]. Here, HLA-E is linked to non-small cell lung carcinoma.